Instem plc Two contract wins in Asia-Pacific
July 16 2014 - 2:01AM
RNS Non-Regulatory
TIDMINS
Instem plc
16 July 2014
Instem plc
("Instem" or the "Company")
Two contract wins in Asia-Pacific
Instem (AIM: INS.L), a leading provider of IT solutions to the
global early development healthcare market, announces that it has
won two new contracts in the Asia-Pacific region.
The first is a five-year contract with the National Shanghai
Center for Drug Safety Evaluation and Research (NCDSER), a leading
Chinese Contract Research Organisation (CRO), which has purchased
Instem's integrated Provantis(R) pre-clinical software suite to
automate laboratory processes at their R&D facility in
Shanghai, China.
The contract was awarded following a detailed competitive
evaluation and is of significant strategic importance as it
strengthens the Company's foothold in the Asia-Pacific region.
Instem's Provantis solution, which is increasingly being recognised
as the industry standard within China and the leading solution
around the world, will replace a combination of in-house developed
applications and legacy systems to provide streamlined processes.
It will be delivered using the SaaS delivery model from Instem's
Shanghai-based data center, adding another large and prestigious
laboratory to Instem's established hosting data centre client
roster.
Commenting on the agreement, Professor Jing Ma, Executive
Director at NCDSER, said: "We are extremely pleased to be deploying
Provantis at our Shanghai facility. We recognise that Instem and
Provantis have fast become the gold standard within China and we
look forward to joining the expanding Provantis user community
within China and across the globe."
A second contract has been signed with an unnamed, leading
Multi-national Corporation, which has purchased Instem's submit(TM)
solution suite to support Clinical Data Interchange Standards
Consortium's (CDISC) Standard for Exchange of Nonclinical Data
(SEND).
SEND defines the organisation, structure, and format of standard
non-clinical tabulation datasets for interchange between
organisations such as sponsors and CROs and for submission to the
US Food and Drug Administration (FDA). Guidance by the FDA was
released earlier in 2014, paving the way for SEND to become a
requirement with pre-clinical study submissions.
The submit(TM) solution, which was launched in 2005 and can be
deployed as a traditional on-site system or accessed over the
Internet using Instem's SaaS model, creates and manages SEND study
datasets throughout their lifecycle and allows sponsors, CROs and
regulators to share, visualise and analyse study data more
efficiently.
Phil Reason, CEO of Instem, said: "We are delighted to have
signed these two agreements in the Asia-Pacific territory. NCDSER
is a recognised centre of excellence within Asia-Pacific and the
contract is of significant strategic importance in terms of
extending our presence within the region. Further to this, the
contract with a leading Multi-national corporation illustrates the
fact our cutting edge technology is being adopted by an increasing
number of respected industry players."
For further information, please contact:
Instem plc www.instem.com
Phil Reason, CEO Tel: +44 (0) 1785 825 600
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser Tel: +44 (0) 20 7496 3000
& Broker)
Richard Lindley
Nick Owen
Walbrook PR Ltd Tel: +44 (0) 20 7933 8780 or instem@walbrookpr.com
Bob Huxford Mob: +44 (0)7747 635 908
Helen Cresswell Mob: +44 (0)7841 917 679
About Instem
Instem is a leading supplier of IT applications to the early
development healthcare market delivering compelling solutionsfor
data collection, management and analysis across the R&D
continuum. Instem applications are in use by customers worldwide,
meeting the rapidly expanding needs of life science and healthcare
organisations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledgethrough the extraction
and harmonisation of actionable scientific information.
Instem supports over 400 clients through full service offices in
the United States, United Kingdom and China with additional
locations in India and a full service distributor based in
Japan.
To learn more about Instem solutions and its mission, please
visit www.instem.com.
About the National Shanghai Center for Drug Safety Evaluation
and Research (NCDSER)
Founded in 1993, NCDSER, also known as Shanghai InnoStar
Bio-Tech Co. Ltd., is a leading pre-clinical Contract Research
Organisation (CRO) based in China. As the first CFDA-certified GLP
laboratory and the most comprehensive and experienced Chinese
toxicology CRO, NCDSER has submitted numerous high quality safety
evaluation studies and IND packages to both CFDA and US FDA. Since
being certified by CFDA in 2003, NCDSER has evaluated a total of
506 compounds, including 417 small molecules, 72 biologics and 17
TCMs.
NCDSER is experienced in designing studies following the
guidelines of different international regulatory authorities
including FDA, OECD and CFDA.
NCDSER serves 300+ clients across North America, Europe and
Asia.
More information: http://www.innostarsh.com/enabout.asp
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASFSFWIFLSESW
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024